UY39958A - Compuestos de imidazopiridazina inhibidores de il-17 - Google Patents

Compuestos de imidazopiridazina inhibidores de il-17

Info

Publication number
UY39958A
UY39958A UY0001039958A UY39958A UY39958A UY 39958 A UY39958 A UY 39958A UY 0001039958 A UY0001039958 A UY 0001039958A UY 39958 A UY39958 A UY 39958A UY 39958 A UY39958 A UY 39958A
Authority
UY
Uruguay
Prior art keywords
inhibitors
compounds
imidazopyridazine compounds
imidazopyridazine
ameliorate
Prior art date
Application number
UY0001039958A
Other languages
English (en)
Spanish (es)
Inventor
C Behenna Douglas
D Goldberg Steven
Deane Gordon
E Hanna Luke
A Loskot Steven
Stefan Mccarver
E Valdes Alexander
Dongpei Wu
Xiaohua Xue
B Rhorer Timothy
Kristen Song
P Meduna Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY39958A publication Critical patent/UY39958A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001039958A 2021-09-27 2022-09-26 Compuestos de imidazopiridazina inhibidores de il-17 UY39958A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US202263367546P 2022-07-01 2022-07-01

Publications (1)

Publication Number Publication Date
UY39958A true UY39958A (es) 2023-04-28

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039958A UY39958A (es) 2021-09-27 2022-09-26 Compuestos de imidazopiridazina inhibidores de il-17

Country Status (16)

Country Link
US (2) US12173007B2 (https=)
EP (1) EP4408847A1 (https=)
JP (1) JP2024536869A (https=)
KR (1) KR20240082369A (https=)
AU (1) AU2022349687A1 (https=)
CA (1) CA3233408A1 (https=)
CL (1) CL2024000867A1 (https=)
CO (1) CO2024003723A2 (https=)
DO (1) DOP2024000051A (https=)
IL (1) IL311751A (https=)
JO (1) JOP20240059A1 (https=)
MX (1) MX2024003772A (https=)
PE (1) PE20240935A1 (https=)
TW (1) TW202330530A (https=)
UY (1) UY39958A (https=)
WO (1) WO2023049887A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ.ベー. イミダゾピリダジンil-17阻害剤化合物
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
KR20250168657A (ko) * 2023-04-11 2025-12-02 다이스 알파, 인크. 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ.ベー. イミダゾピリダジンil-17阻害剤化合物
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
JP2024536869A (ja) 2024-10-08
WO2023049887A1 (en) 2023-03-30
JOP20240059A1 (ar) 2024-03-26
KR20240082369A (ko) 2024-06-10
US20230143050A1 (en) 2023-05-11
MX2024003772A (es) 2024-06-19
CO2024003723A2 (es) 2024-04-18
EP4408847A1 (en) 2024-08-07
US20250109137A1 (en) 2025-04-03
DOP2024000051A (es) 2024-11-15
US12173007B2 (en) 2024-12-24
PE20240935A1 (es) 2024-04-30
TW202330530A (zh) 2023-08-01
CA3233408A1 (en) 2023-03-30
IL311751A (en) 2024-05-01
CL2024000867A1 (es) 2024-09-23
AU2022349687A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
UY39958A (es) Compuestos de imidazopiridazina inhibidores de il-17
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
UY39957A (es) Compuestos de imidazopiridazina inhibidores de il-17
BR112023016299A2 (pt) Composições e métodos para inibir kras
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CR20120001A (es) Compuestos terapeuticos y composiciones
NI201500140A (es) Compuestos y composiciones terapéuticos
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
BR112019007591A2 (pt) inibidores de bromodomínios
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
MX2018000539A (es) Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos.
AR127149A1 (es) Compuestos de imidazopiridazina inhibidores de il-17
CL2022002989A1 (es) Imidazopiridazinas como moduladores de il-17.
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).